Assenagon Asset Management S.A. Takes $10.48 Million Position in Bausch Health Companies Inc (BHC)

Assenagon Asset Management S.A. acquired a new stake in Bausch Health Companies Inc (NYSE:BHC) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 408,389 shares of the company’s stock, valued at approximately $10,483,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Moody Lynn & Lieberson LLC acquired a new position in Bausch Health Companies in the third quarter valued at $486,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Bausch Health Companies in the third quarter valued at about $378,000. Alps Advisors Inc. purchased a new stake in shares of Bausch Health Companies in the third quarter valued at about $211,000. Oakworth Capital Inc. purchased a new stake in shares of Bausch Health Companies in the third quarter valued at about $208,000. Finally, IFP Advisors Inc purchased a new stake in shares of Bausch Health Companies in the third quarter valued at about $728,000. Institutional investors own 43.28% of the company’s stock.

BHC has been the topic of several analyst reports. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 target price on the stock in a report on Wednesday, October 3rd. ValuEngine downgraded shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Piper Jaffray Companies set a $16.00 target price on shares of Bausch Health Companies and gave the company a “sell” rating in a report on Tuesday, August 7th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a report on Monday, August 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $32.00 target price on shares of Bausch Health Companies in a report on Wednesday, September 12th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.89.



In related news, EVP Christina Ackermann sold 19,946 shares of the business’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Schutter Richard U. De acquired 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The shares were bought at an average cost of $23.96 per share, for a total transaction of $2,995,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 165,000 shares of company stock worth $3,890,700. 11.54% of the stock is owned by insiders.

Shares of NYSE:BHC opened at $22.88 on Thursday. The stock has a market capitalization of $7.76 billion, a PE ratio of 5.78, a PEG ratio of 0.32 and a beta of -0.48. The company has a current ratio of 1.14, a quick ratio of 0.89 and a debt-to-equity ratio of 6.99. Bausch Health Companies Inc has a fifty-two week low of $10.94 and a fifty-two week high of $28.45.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.12. The business had revenue of $2.13 billion for the quarter, compared to the consensus estimate of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. On average, equities analysts predict that Bausch Health Companies Inc will post 3.46 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

See Also: How Buying a Call Option Works

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply